Company page

Arvinas, Inc.

Arvinas, Inc. is a public company traded under the ticker ARVN in the American market, with a market capitalization of approximately $494.9 million. The company focuses on developing innovative therapies for various diseases through its proprietary protein degradation technology. Arvinas aims to address unmet medical needs and improve patient outcomes with its advanced drug candidates.